Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases
José Luis Morgado‐Pascual, Sandra Rayego‐Mateos, Lucía Tejedor-Santamaria, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Kidney fibrosis: from mechanisms to therapeutic medicines
Rongshuang Huang, Ping Fu, Liang Ma
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 260
Targeting inflammation to treat diabetic kidney disease: the road to 2030
Sandra Rayego‐Mateos, Raúl R. Rodrigues-Díez, Beatriz Fernández‐Fernández, et al.
Kidney International (2022) Vol. 103, Iss. 2, pp. 282-296
Closed Access | Times Cited: 145
Epigenetic regulator BRD4 is involved in cadmium-induced acute kidney injury via contributing to lysosomal dysfunction, autophagy blockade and oxidative stress
Zhonggui Gong, Yuan Zhao, Zhen‐Yong Wang, et al.
Journal of Hazardous Materials (2021) Vol. 423, pp. 127110-127110
Closed Access | Times Cited: 130
Histone Modifications and Non-Coding RNAs: Mutual Epigenetic Regulation and Role in Pathogenesis
Irina V. Bure, М. В. Немцова, Ekaterina Kuznetsova
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5801-5801
Open Access | Times Cited: 93
Target c-Myc to treat pancreatic cancer
Moein Ala
Cancer Biology & Therapy (2022) Vol. 23, Iss. 1, pp. 34-50
Open Access | Times Cited: 92
Chronic Kidney Disease: Strategies to Retard Progression
Ming-Tso Yan, Chia‐Ter Chao, Shih‐Hua Lin
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 10084-10084
Open Access | Times Cited: 78
Renin-angiotensin system and inflammation update
Elena Cantero‐Navarro, Beatriz Fernández‐Fernández, Adrián M. Ramos, et al.
Molecular and Cellular Endocrinology (2021) Vol. 529, pp. 111254-111254
Closed Access | Times Cited: 77
Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?
Tamás Németh, György Nagy, Thomas Pap
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 8, pp. 1055-1064
Open Access | Times Cited: 53
Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease
Julio M. Martínez‐Moreno, Miguel Fontecha‐Barriuso, Diego Martín‐Sánchez, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 11, pp. 4113-4113
Open Access | Times Cited: 54
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease
Parvez Κhan, Jawed A. Siddiqui, Shailendra Kumar Maurya, et al.
Seminars in Cancer Biology (2020) Vol. 83, pp. 57-76
Open Access | Times Cited: 51
Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development
Juncheng Chen, Pan Tang, Yuxi Wang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 7, pp. 5184-5211
Closed Access | Times Cited: 36
BRD9-mediated chromatin remodeling suppresses osteoclastogenesis through negative feedback mechanism
Jiahui Du, Yili Liu, Xiaolin Wu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 21
BRD4: An emerging prospective therapeutic target in glioma
Hua Yang, Li Wei, Yang Xun, et al.
Molecular Therapy — Oncolytics (2021) Vol. 21, pp. 1-14
Open Access | Times Cited: 37
Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis
Min Wang, Zhaohui Huang, Xin Li, et al.
Pharmacological Research (2024) Vol. 207, pp. 107306-107306
Open Access | Times Cited: 5
βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapies
Arun Kanakkanthara, John H. Miller
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 2, pp. 188607-188607
Open Access | Times Cited: 28
BRD4 methylation by the methyltransferase SETD6 regulates selective transcription to control mRNA translation
Zlata Vershinin, Michal Feldman, Thilo Werner, et al.
Science Advances (2021) Vol. 7, Iss. 22
Open Access | Times Cited: 27
Revisiting metallodrugs for the treatment of skin cancers
Carlos Marrote Manzano, Douglas Hideki Nakahata, Raphael Enoque Ferraz de Paiva
Coordination Chemistry Reviews (2022) Vol. 462, pp. 214506-214506
Open Access | Times Cited: 22
Histone Acetylation and Modifiers in Renal Fibrosis
Fengchen Shen, Shougang Zhuang
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
Emerging roles of BET proteins in transcription and co‐transcriptional RNA processing
Nicole Eischer, Mirjam Arnold, Andreas Mayer
Wiley Interdisciplinary Reviews - RNA (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 19
AT1, a small molecular degrader of BRD4 based on proteolysis targeting chimera technology alleviates renal fibrosis and inflammation in diabetic nephropathy
Meng Yang, Jialin Li, Xiaocui Huang, et al.
Bioorganic Chemistry (2025) Vol. 156, pp. 108184-108184
Closed Access
Design of Selective BRD4 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease
Yueyue Yang, Hongli Liu, Haoxing Yuan, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Discovery of Highly Potent BET Inhibitors based on a Tractable Tricyclic Scaffold
J. H. Zaidi, Eleonora Comeo, Andrew Baxter, et al.
ACS Medicinal Chemistry Letters (2025) Vol. 16, Iss. 4, pp. 588-595
Open Access
Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Rahul Aggarwal, Alexander Starodub, Brian D. Koh, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 18, pp. 3979-3989
Open Access | Times Cited: 16
Inhibition of BRD4 Attenuates ER Stress-induced Renal Ischemic-Reperfusion Injury
Paula Díaz-Bulnes, Ramón María Alvargonzález Rodríguez, Elisenda Bañón-Maneus, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 5, pp. 1547-1562
Open Access | Times Cited: 3
Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma
Sirapa Vichaikul, Mikel Gurrea‐Rubio, M. Asif Amin, et al.
JCI Insight (2022) Vol. 7, Iss. 9
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top